Eventide Asset Management LLC Takes $8.58 Million Position in enGene Holdings Inc. $ENGN

Eventide Asset Management LLC acquired a new stake in shares of enGene Holdings Inc. (NASDAQ:ENGN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 950,000 shares of the company’s stock, valued at approximately $8,578,000.

A number of other hedge funds have also made changes to their positions in the stock. PFS Partners LLC increased its holdings in shares of enGene by 22.2% during the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after acquiring an additional 2,000 shares during the last quarter. Millennium Management LLC increased its holdings in shares of enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after acquiring an additional 7,472 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares during the last quarter. Cresset Asset Management LLC acquired a new position in shares of enGene during the 2nd quarter valued at about $36,000. Finally, Paloma Partners Management Co acquired a new position in shares of enGene during the 2nd quarter valued at about $38,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Stock Performance

ENGN opened at $1.62 on Monday. The firm has a market capitalization of $108.52 million, a P/E ratio of -0.72 and a beta of -0.29. The stock’s 50 day moving average price is $4.41 and its two-hundred day moving average price is $7.24. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene Holdings Inc. has a 12-month low of $1.40 and a 12-month high of $12.25.

Analysts Set New Price Targets

ENGN has been the topic of a number of research analyst reports. Wall Street Zen lowered enGene from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Piper Sandler lowered enGene from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $7.00 to $4.00 in a report on Friday, May 8th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $2.00 target price (down from $25.00) on shares of enGene in a report on Friday, May 8th. Weiss Ratings lowered enGene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 15th. Finally, Oppenheimer lowered enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, enGene presently has a consensus rating of “Hold” and a consensus price target of $12.68.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.